Mendus: Phase III Win for AML Vaccine Supports Vididencel - Redeye
A cancer vaccine has now shown a survival benefit as AML maintenance treatment in a randomised phase III trial. We believe this strengthens the case for Mendus’ vididencel and improves the environment for funding and partnering.
ANNONS
A cancer vaccine has now shown a survival benefit as AML maintenance treatment in a randomised phase III trial. We believe this strengthens the case for Mendus’ vididencel and improves the environment for funding and partnering.